NCT01541423已完成不适用
A European Multi-Center, Multi-Country, Post-Authorisation, Observational Study (Registry) Of Patients With Hereditary Angioedema (HAE) Who Are Administered CINRYZE® (C1 Inhibitor [Human]) For The Treatment Or Prevention Of HAE Attacks
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Shire
- 入组人数
- 83
- 试验地点
- 20
- 主要终点
- Incidence of adverse drug reactions
研究概览
简要总结
This observational (non-interventional) study is being conducted to characterize the safety and use of CINRYZE in routine clinical practice when administered for (1) routine prevention of angioedema attacks, (2) pre-procedure prevention of angioedema attacks, and/or (3) treatment of angioedema attacks.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Incidence of adverse drug reactions
时间窗: 12 months
Occurrence of pregnancy
时间窗: 12 months
Incidence of thrombotic/thromboembolic events
时间窗: 12 months
次要结局
未报告次要终点
研究者
研究点 (20)
Loading locations...
相似试验
已完成
不适用
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid CancerSymptomatic, Aggressive, Sporadic, Unresectable, LocallyAdvanced/Metastatic Medullary Thyroid Cancer (MTC)NCT01945762Genzyme, a Sanofi Company31
终止
不适用
European Non-interventional Study on Refractory Epilepsy With Developmental DelayDevelopment DelayRefractory EpilepsyNCT04398667Zogenix, Inc.93
已完成
不适用
Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes MellitusDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT02392117Novo Nordisk A/S1,262
已完成
不适用
Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 TreatmentDiabetesDiabetes Mellitus, Type 2NCT01548235Novo Nordisk A/S423
已完成
不适用
Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia ACongenital Bleeding DisorderHaemophilia ANCT02035384Novo Nordisk A/S69